Article
Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
Cancer chemotherapy and pharmacology - 1 Jul 2016
Yamashita Takaya, Fujishima Naohito, Miura Masatomo, Niioka Takenori, Abumiya Maiko, Shinohara Yoshinori, Ubukawa Kumi, Nara Miho, Fujishima Masumi, Kameoka Yoshihiro, Tagawa Hiroyuki, Hirokawa Makoto, Takahashi Naoto
Abstract excerpt
BACKGROUND: Tacrolimus is metabolized by cytochrome P450 (CYP) 3A4 and 3A5. We investigated the influence of CYP3A5 polymorphism and concurrent use of azole antifungal agents (AZ) on the pharmacokinetics of a once-daily modified-release tacrolimus formulation (Tac-QD) in patients after hematopoietic stem cell transplantation (HSCT). DESIGN AND METHODS: Twenty-four patients receiving allogeneic HSCT were enrolled....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.